涨停揭秘 | 昭衍新药首板涨停，封板资金6286.29万元

金融界04-09

4月9日，昭衍新药收盘首板涨停，截至当日收盘，昭衍新药报18.96元/股，成交额3.46亿元，总市值142.18亿元，封板资金6286.29万元。涨停原因：CRO+创新药公司主要专注于提供药物全生命周期的安全性评估和监测服务，其中核心业务是非临床研究服务，包括新药的临床申报到注册上市的全流程服务和药物发现阶段的CRO外包服务。该公司的CRO外包服务主要针对创新药研发的早期阶段，从靶点筛选验证到临床...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2426217159?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-09 16:34","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2426217159","market":"hk","top_or_hot":-1,"title":"涨停揭秘 | 昭衍新药首板涨停，封板资金6286.29万元","media":"金融界","content":"<div>\n<p>4月9日，昭衍新药收盘首板涨停，截至当日收盘，昭衍新药报18.96元/股，成交额3.46亿元，总市值142.18亿元，封板资金6286.29万元。涨停原因：CRO+创新药公司主要专注于提供药物全生命周期的安全性评估和监测服务，其中核心业务是非临床研究服务，包括新药的临床申报到注册上市的全流程服务和药物发现阶段的CRO外包服务。该公司的CRO外包服务主要针对创新药研发的早期阶段，从靶点筛选验证到临床...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091634388758f479&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>涨停揭秘 | 昭衍新药首板涨停，封板资金6286.29万元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n涨停揭秘 | 昭衍新药首板涨停，封板资金6286.29万元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-09 16:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091634388758f479&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月9日，昭衍新药收盘首板涨停，截至当日收盘，昭衍新药报18.96元/股，成交额3.46亿元，总市值142.18亿元，封板资金6286.29万元。涨停原因：CRO+创新药公司主要专注于提供药物全生命周期的安全性评估和监测服务，其中核心业务是非临床研究服务，包括新药的临床申报到注册上市的全流程服务和药物发现阶段的CRO外包服务。该公司的CRO外包服务主要针对创新药研发的早期阶段，从靶点筛选验证到临床...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091634388758f479&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06127","symbol_name":"昭衍新药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091634388758f479&s=b","article_id":"2426217159","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091634388758f479&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2426217159","pubTimestamp":1712651667,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"4月9日，昭衍新药收盘首板涨停，截至当日收盘，昭衍新药报18.96元/股，成交额3.46亿元，总市值142.18亿元，封板资金6286.29万元。目前，公司已经建立了体外和体内药效筛选评价平台以及早期成药性筛选评价平台，为创新药企提供早期发现服务。业绩方面，2023年1月-12月，昭衍新药实现营业收入23.76亿元，同比增长4.78%；归属净利润3.97亿元，同比减少63.04%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603127":"昭衍新药","06127":"昭衍新药","BK1576":"医药外包概念","BK1141":"生命科学工具和服务"},"translate_title":"The daily limit reveals the daily limit of the first board of Zhaoyan New Drug, and the closing fund is 62.8629 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603127":0.9,"06127":1},"content_text":"4月9日，昭衍新药收盘首板涨停，截至当日收盘，昭衍新药报18.96元/股，成交额3.46亿元，总市值142.18亿元，封板资金6286.29万元。涨停原因：CRO+创新药公司主要专注于提供药物全生命周期的安全性评估和监测服务，其中核心业务是非临床研究服务，包括新药的临床申报到注册上市的全流程服务和药物发现阶段的CRO外包服务。该公司的CRO外包服务主要针对创新药研发的早期阶段，从靶点筛选验证到临床候选分子的确定，提供全流程一体化的生物学评价支持。目前，公司已经建立了体外和体内药效筛选评价平台以及早期成药性筛选评价平台，为创新药企提供早期发现服务。业绩方面，2023年1月-12月，昭衍新药实现营业收入23.76亿元，同比增长4.78%；归属净利润3.97亿元，同比减少63.04%。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426217159"}